Combination of methylprednisolone and rosiglitazone promotes recovery of neurological function aTher spinal cord injury

Xi-gong Li, Xiang-jin Lin, Jun-hua Du, San-zhong Xu, Xian-feng Lou, Zhong ChenDepartment of Orthopedic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China

Combination of methylprednisolone and rosiglitazone promotes recovery of neurological function aTher spinal cord injury

Xi-gong Li, Xiang-jin Lin, Jun-hua Du*, San-zhong Xu, Xian-feng Lou, Zhong Chen
Department of Orthopedic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China

How to cite this article: Li XG, Lin XJ, Du JH, Xu SZ, Lou XF, Chen Z (2016) Combination of methylprednisolone and rosiglitazone promotes recovery of neurological function aTher spinal cord injury. Neural Regen Res 11(10)∶1678-1684.

Open access statement: This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Jun-hua Du, M.D.,

zyorthopaedic@yahoo.com.cn. orcid:

0000-0002-0786-3410

(Jun-hua Du)

Accepted: 2016-09-07

Graphical Abstract

Methylprednisolone exhibits anti-inflammatory antioxidant properties, and rosiglitazone acts as an anti-inflammatory and antioxidant by activating peroxisome proliferator-activated receptor-γ in the spinal cord. Methylprednisolone and rosiglitazone have been clinically used during the early stages of secondary spinal cord injury. Because of the complexity and diversity of the inflammatory process aTher spinal cord injury, a single drug cannot completely inhibit inflammation. Therefore, we assumed that a combination of methylprednisolone and rosiglitazone might promote recovery of neurological function aTher secondary spinal cord injury. In this study, rats were intraperitoneally injected with methylprednisolone (30 mg/kg) and rosiglitazone (2 mg/kg) at 1 hour aTher injury, and methylprednisolone (15 mg/kg) at 24 and 48 hours aTher injury. Rosiglitazone was then administered once every 12 hours for 7 consecutive days. Our results demonstrated that a combined treatment with methylprednisolone and rosiglitazone had a more pronounced effect on attenuation of inflammation and cell apoptosis, as well as increased functional recovery, compared with either single treatment alone, indicating that a combination better promoted recovery of neurological function aTher injury.

nerve regeneration; spinal cord injury; methylprednisolone; rosiglitazone; inflammation; drug therapy; anti-inflammatory agents; functional recovery; neural regeneration

Introduction

Spinal cord injury (SCI) results in neurological deficits and motor dysfunction (Rintala et al., 1998). The pathophysiology of acute SCI is complex and two mechanisms can be distinguished as primary and secondary damage (Collins, 1983); primary traumatic mechanical injury to the spinal cord induces death in a number of neurons that cannot be recovered or regenerated (Profyris et al., 2004). These events are then exacerbated by secondary damage, including a variety of biochemical and pathological processes that begin within minutes aTher initial injury and continue for days and weeks (Diaz-Ruiz et al., 2002; Hausmann, 2003).

Several pharmacological agents have been developed to attenuate secondary damage and to maximize the extent of spared neurologic tissue following SCI. Methylprednisolone (MP) is a pharmacological agent used early in the treatment of experimental and human SCI because of the anti-inflammatory actions and potent anti-oxidation effects mediated by suppression of nuclear factor kappa B binding (Hsu and Dimitrijevic, 1990; Hall, 1992; Short et al., 2000; Nadeau and Rivest, 2003; Sayer et al., 2006). However, MP application is only effective within a relatively narrow time window after SCI. The onset of glucocorticoid receptor expression within the spinal cord is rapid, but is only transiently induced fol-lowing traumatic injury (Yan et al., 1999), perhaps explaining the very limited therapeutic window of MP. Some studies have proposed the use of MP in combined treatments as an initial neuroprotective therapy coupled with pro-regenerative or other treatments (Baffour et al., 1995; Nash et al., 2002; Takami et al., 2002). Rosiglitazone (RSG), one type of thiazolidinedione, is a synthetic agonist of the ligand-activated transcription factor peroxisome proliferator-activated receptor-γ. Recent studies have shown that RSG exhibits anti-inflammatory and anti-oxidant properties in animal models of acute central nervous system insults involving focal cerebral ischemia, SCI, and traumatic brain injury (Sundararajan et al., 2005; Pereira et al., 2006; Park et al., 2007; Hyong et al., 2008).

However, based on the complexity and redundancy of the inflammatory response following SCI, it is unlikely that a single target can achieve complete inhibition of inflammation. The therapeutic effects of simultaneous administration of MP and RSG have not previously been evaluated. Therefore, the purpose of the present study was to investigate the neuroprotective effect of simultaneous administration of MP and RSG on experimental SCI, and to determine whether these mechanistically distinct pharmacological reagents can act synergistically.

Materials and Methods

Experimental animals

Ninety-six adult male Sprague-Dawley rats aged 10—12 weeks and weighing 200—250 g were provided by the Laboratory Animal Center of Zhejiang Province of China (SCXK (Zhe) 2014-0001). All animal experiments were approved by the Ethics Committee for Animal Experiments of Zhejiang University of China. Every effort was made to minimize the number and suffering of the animals used in the following experiments, in accordance with the United States National Institutes of Health Guide for the Care and Use of Laboratory Animal (NIH Publication No. 85-23, revised 1986).

Methods

Model establishment and administration

Rats were intraperitoneally anesthetized using chloral hydrate (400 mg/kg). A longitudinal incision was made on the midline of the back, exposing the paravertebral muscles. The spinal cord was exposed via a four-level T5—8laminectomy, and compressive SCI was produced by transient extradural application of an aneurysm clip, which exerted a closing force of approximately 24 g on the spinal cord at T6—7levels for 1 minute. This technique created a model of complete and irreversible SCI with complete paralysis of the lower extremities (Rivlin and Tator, 1978). ATher removal of the clip, the skin incision was closed and the rats were singly housed in a temperature-controlled room at 27°C for a survival period of 28 days. Manual massage of urinary bladder was performed twice daily until autonomous bladder voidance reflex developed.

The 96 rats were randomly allocated into six groups (n = 16). In the sham group, rats were subjected to laminectomy alone. In the SCI group, rats received laminectomy with SCI. In the SCI + vehicle group, rats were intraperitoneally injected with 0.9% saline after SCI. In the SCI + MP group, rats were intraperitoneally injected with MP (30 mg/kg at 1 hour, 15 mg/kg at 24 and 48 hours; Mustafa Nevzat Ilac Sanayi A.S.,Turkey) after SCI. In the SCI + MP + RSG group, rats were intraperitoneally injected with RSG (2 mg/kg at 1 hour, and once every 12 hours for 7 days; Avandia GlaxoSmith-Kline, Philadelphia, PA, USA) after SCI. In the combined treatment group, rats were intraperitoneally injected with MP (30 mg/kg at 1 hour, 15 mg/kg at 24 and 48 hours) and RSG (2 mg/kg at 1 hour, and once every 12 hours for 7 days) after SCI. Among 16 rats, 10 were sacrificed 24 hours aTher SCI for myeloperoxidase (MPO), enzyme linked immunosorbent assay (ELISA), terminal dexynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL), and western blot assays; the remaining six rats were used for functional assessment. The dose regimen used in the present study was chosen based on results from our preliminary dose-dependent study.

MPO activity assay

MPO activity, an indicator of neutrophil infiltration, was determined in spinal cord tissues at 24 hours post-injury as previously described (Mullane, 1989). MPO activity was measured in each sample according to manufacture instructions (Nanjing Jiancheng Biological Institute, Nanjing, China) and was recorded at U/g wet tissue.

Protein expression of tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β)

Portions of spinal cord tissues collected at 24 hours after SCI were rapidly dissected and homogenized in 1 mL PBS containing protease inhibitors. TNF-α and IL-1β expression levels were assayed using the DuoSet ELISA Development System (R&D Systems Inc., Minneapolis, MN, USA). All assays were performed in duplicate using recommended buffers, diluents, and substrates. Standard samples and tissue samples were aliquoted into 96-well plates, and the optical density at 450 nm was measured for each well using a microplate reader. The optical densities for each sample were compared with a standard TNF-α and IL-1β concentration curve created in Excel to quantify serum TNF-α and IL-1β expression.

TUNEL assay

TUNEL assay was conducted using a TUNEL detection kit according to manufacture instructions (Roche, Basel, Switzerland) at 24 hours after SCI (Darzynkiewicz, 2008). Slides were observed by light microscopy and neurons with brown-stained nuclei or containing apoptotic bodies were considered apoptotic. All TUNEL-positive cells were counted and examined for typical pathological features of apoptosis. The mean number of TUNEL-positive cells in each group was calculated, and the apoptotic index was expressedas (TUNEL-positive cells/total cells) × 100%. Independent scoring was performed by a blinded investigator.

Western blot assay of Bax and Bcl-2 protein expression

Western blot assay was performed to determine expression of Bax and Bcl-2 protein within the injured spinal cord at 24 hours after SCI. Tissue samples from SCI-injured animals were collected and homogenized on ice in 10 mM Tris-HCl buffer (pH 7.4), 10 mM ethylenediamine tetraacetic acid, 30% TritonX-100, 10% sodium dodecyl sulfate, and NaCl using a homogenizer. Supernatant was collected and stored at —80°C. Samples (40 μg total protein/well) were subjected to 10—14% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and were electro-transferred to nitrocellulose membranes. The membranes were then blocked in 10% non-fat dry milk in saline buffer for 1 hour and incubated in primary antibodies specific to Bax, Bcl-2, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 4°C. Membranes were blocked in 10% non-fat milk for 1 hour at 37°C, then incubated in rabbit anti-rat Bax, rabbit anti-rat Bcl-2, or rabbit anti-rat GAPDH antibodies (all 1:400; Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 4°C. ATher washing three times with 0.1 M Tris buffered saline (pH 7.2) containing 0.1% Tween-20 (TBST) (10 minutes each), membranes were incubated with peroxidase-conjugated bovine anti-rabbit immunoglobulin G (1:2,000; Santa Cruz Biotechnology) for 2 hours at 37°C and washed three times with TBST (10 minutes each). Immunoreactive protein bands were visualized by enhanced chemiluminescence, according to manufacture instructions (Pierce, Rockford, IL, USA). Band optical density values were determined using Gel-Pro Analyzer SoThware, version 4.0 (Media Cybernetics, USA), and Bax and Bcl-2 optical density values were expressed relative to GAPDH.

Basso, Beattie, and Bresnahan (BBB) assessment

Functional assessment was performed using the BBB (Basso et al., 1995) locomotor recovery scale on postoperative days 3, 7, 14, 21, and 28. The scale was based on the precise observation of hindlimb movements, stepping, and coordination in an open field. Rats were observed for 4 minutes by an observer blinded to the treatments and their behaviors were scored from 0 (no spontaneous locomotor activity) to 21 (normal movement-coordinated gait, with parallel paw placement). Scores from 0 to 7 indicate return of isolated movements in the hip, knee, and ankle joints. Scores from 8 to 13 indicate return of paw placement and coordinated movements with the forelimbs. Scores from 14 to 21 show return of toe clearance during stepping, predominant paw position, trunk stability, and tail position. Scores are represented as the average score of all animals (n = 6) in each group at each time point.

Statistical analysis

Data are expressed as the mean ± SD and were analyzed with SPSS 13.0 soThware (SPSS, Chicago, IL, USA). Multiple group comparisons of differences in quantitative measurement were made using one-way analysis of variance followed by Dunnett’s t-test. A value of P ＜ 0.05 was considered statistically significant.

Results

MPO activity aTher SCI

We investigated the effect of combined treatment with MP and RSG on MPO activity (Figure 1). MPO activity was significantly elevated in the spinal cord at 24 hours post-injury in rats with SCI compared with sham-operated rats (P ＜ 0.01). MPO activity was significantly attenuated by early treatment with MP or RSG alone (P ＜ 0.05). The protective effect of single treatment was further significantly enhanced by combined treatment with MP and RSG (P ＜ 0.05).

Effects of combined treatment with MP and RSG on TNF-α and IL-1β expression aTher SCI

To determine whether combined treatment with MP and RSG modulates the inflammatory process by regulating secretion of pro-inflammatory cytokines, we analyzed TNF-α and IL-1β expression levels (Figure 2). Rats with SCI showed dramatically up-regulated TNF-α and IL-1β expression in the injured regions of the spinal cord compared with rats with an intact spinal cord (P ＜ 0.01). Although MP or RSG treatment alone significantly reduced TNF-α and IL-1β levels at 24 hours post-injury (P ＜ 0.05), TNF-α and IL-1β levels were lower in the SCI + MP + RSG group than in the SCI + RSG group (P ＜ 0.05).

Effects of combined treatment with MP and RSG on cell apoptosis aTher SCI

Almost no apoptotic cells were detected in the spinal cords of sham-operated rats (Figure 3A). However, many TUNEL-positive cells were observed within spinal cord tissues from non-treated and vehicle-treated rats (P ＜ 0.01; Figures 3B, C).

MP, RSG, and the combination of both significantly reduced the number of TUNEL-positive cells compared with vehicle-treatment (P ＜ 0.05; Figure 3D—F). However, there was a significant difference between the SCI + MP + RSG group and the SCI + MP and SCI + RSG groups (P ＜ 0.05).

Effects of combined treatment with MP and RSG on Bax and Bcl-2 expression aTher SCI

At 24 hours post-injury, Bax levels were appreciably increased in the spinal cord of rats subjected to SCI. Bcl-2 expression was significantly decreased in whole extracts obtained from spinal cord tissues at 24 hours after SCI. MP and RSG administered as a single treatment significantly reduced SCI-induced Bax expression and blunted SCI-induced inhibition of Bcl-2 expression, respectively. However, combined treatment with MP and RSG had a more pronounced effect on SCI-induced Bax and Bcl-2 expression (Figure 4).

Effects of combined treatment with MP and RSG on functional recovery aTher SCI

BBB locomotor recovery scale aTher SCI in all six groups is shown in Figure 5. Spinal cord contusion resulted in a score of 0 with bilateral hind limb paralysis in all rats subjected to SCI. Although spontaneous recovery of function was observed over the next 3 weeks aTher SCI, neurological function in rats of the SCI + MP group, SCI + RSG group, and SCI + MP + RSG group improved more rapidly and showed statistically significantly better scores compared with the SCI group and SCI + vehicle group (P ＜ 0.05). However, there was a significant difference in BBB locomotor recovery scales between combined treatment group and single treatment group from 3 to 21 days aTher injury (P ＜ 0.05).

Discussion

The current study demonstrated that combined treatment with MP and RSG after spinal cord contusion significantly suppressed infiltration of neutrophils, proinflammatory cytokine expression, and occurrence of neuronal apoptosis compared with MP or RSG alone. The combined treatment group also exhibited greater locomotor recovery during the 3-week follow-up period. The difference in neurological and histological outcomes between the single and combined treatment groups could be explained by the synergistic or additive effect of MP and RSG during the acute phase of SCI.

The neuroprotective effects of high-dose MP on SCI have been previously reported. Anti-inflammatory actions and reduction of lipid peroxidation have been postulated to be the two major factors in improved outcomes associated with MP (Hsu et al., 1990; Hall, 1992; Nadeau and Rivest, 2003). RSG is a novel experimental therapy for SCI that mitigates secondary damage by activating peroxisome proliferator-activated receptor-γ in the central nervous system. Peroxisome proliferator-activated receptor-γ is a ligand-activated transcription factor from the nuclear hormone receptor superfamily, and is thought to modulate multiple cellular functions, including glucose absorption, lipid metabolism, cell growth and differentiation, apoptosis, and inflammation (Tolman and Chandramouli, 2003). Recent studies showed that RSG is extremely neuroprotective in animal models of acute central nervous system insults, including neurodegonerative diseases, focal ischemia, SCI, and surgical trauma (Sundararajan et al., 2005; Pereira et al., 2006; Park et al., 2007; Hyong et al., 2008; Madeira et al., 2015). However, it is unrealistic to achieve disease remission by blocking a single early mediator in the inflammatory cascade, because a large number of inflammatory mediators are involved in the secondary injury processes after SCI. Therefore, combination therapies with drugs that can target more than one mechanism are beneficial. Additionally, compounds that simultaneously target multiple pathways can be more effective.

Secondary degeneration after traumatic SCI is affected by a variety of cellular and molecular mechanisms. Inflammation is one important mechanism that may exacerbate the effects of primary mechanical trauma. During the acute phase of SCI, an inflammatory reaction develops within hours aTher initial injury and is characterized by the neutrophil infiltration and microglial activation (McTigue et al., 1989). These reactive cells produce several proinflammatory cytokines, including IL-1, TNF-α, IL-6, and IL-3, which mediate the inflammatory response and regulate cellular events aTher SCI.

The proinflammatory cytokines TNF-α and IL-1β play an important function in the induction of inducible nitric oxide synthase, which is known to have a key role in the development of SCI (Genovese et al., 2006). Several experimental studies have confirmed that TNF-α and IL-1β levels in the injured spinal cord are significantly upregulated within the first few hours aTher SCI, which significantly influences the degree of secondary injury aTher SCI (Blight, 1992). Even within 1 hour after injury, increased TNF-α and IL-1β mRNA expression is detected within the spinal cord (Bartholdi and Schwab, 1997; Wang et al., 1997). In the current study, the number of MPO-positive neutrophils and TNF-α and IL-1β expression were significantly increased in the injured rats compared with sham-operated rats at 24 hours post-injury. Although, to a certain extent, administration of MP or RSG alone reduced the inflammatory response following SCI, the combined treatment attenuated infiltration of neutrophils and upregulated TNF-α and IL-1β expression to a greater degree within spinal cord aTher injury.

The current study also demonstrated that the number of TUNEL-positive cells in the combined treatment group was significantly less than in the single treatment groups at the injury site. Recent studies have revealed that most neuronal and glial cell loss aTher injury results from apoptosis (Charriaut-Marlangue et al., 1996; Crowe et al., 1997; Kato et al., 1997; Liu et al., 1997). Additionally, apoptotic death of oligodendrocytes is also observed along the longitudinal axis of the spinal cord, which is involved in the delayed and prolonged process of demyelination and deterioration of sensorimotor function of the cord (Abe et al., 1999). Therefore, interventions targeting apoptosis may be beneficial for preventing secondary degeneration following traumatic SCI. Apoptosis can be triggered by intracellular and extracellular signals and involves a complex cascade of molecular and biochemical reactions in the cell. It has been well demonstrated that Bax, a pro-apoptotic gene, plays an important role in developmental cell death and in central nervous system injury (Wu et al., 2006). Likewise, administration of Bcl-2 protein into the injured spinal cord increases neuronal survival, suggesting that the SCI-induced decrease in Bcl-2 expression contributes considerably to neuronal death (Lu et al., 2006). In this study, Bax levels appreciably increased in spinal cords from rats subjected to SCI at 24 hours post-injury, while Bcl-2 expression significantly decreased in SCI rats at 24 hours post-injury. Combined treatment with MP and RSG significantly decreased Bax expression and increased Bcl-2 expression following SCI. These results suggest that combined treatment reduced apoptotic cell death by preventing the attenuation of the anti-apoptotic pathway and blocking activation of thepro-apoptotic pathway.

During the 3-week follow-up period, gradual functional recovery was assessed using the BBB locomotor recovery scale in all rats with SCI. However, BBB scores were significantly better in the combined treatment group than in other experimental groups. Better BBB scores indicated improved coordination between different muscles, better timing sequence and scaling of muscle activity, and progress in inter-joint and inter-limb coordination. These findings demonstrated that combined treatment with MP and RSG significantly increased recovery of motor function in SCI rats. Our results suggested that RSG administration after spinal cord contusion attenuated inflammatory reactions and diminished apoptosis, resulting in improved locomotor activity.

Figure 1 Effects of combined treatment with MP and RSG on MPO activity.

Figure 2 Effects of combined treatment with MP and RSG on TNF-α and IL-1β expression.

Figure 3 Effects of combined treatment with MP and RSG on cell apoptosis aTher SCI.

Figure 4 Effects of combined MP and RSG treatment on Bax and Bcl-2 expression at 24 hours aTher SCI.

Figure 5 Effects of combined treatment with MP and RSG on locomotor activity during 4 weeks following SCI.

In conclusion, the strategies targeting multiple proinflammatory pathways may be more effective than targeting a single effector molecule. Combined treatment with MP and RSG exerts therapeutic effects on SCI.

Author contributions: All authors participated in study design, performed experiments, assessed data, and approved the final version of the paper.

Conflicts of interest: None declared.

Plagiarism check: This paper was screened twice using CrossCheck to verify originality before publication.

Peer review: This paper was double-blinded and stringently reviewed by international expert reviewers.

References

Abe Y, Yamamoto T, Sugiyama Y, Watanabe T, Saito N, Kayama H, Kumagai T (1999) Apoptotic cells associated with Wallerian degeneration aTher experimental spinal cord injury: a possible mechanism of oligodendroglial death. J Neurotrauma 16:946-952.

Baffour R, Achanta K, Kaufman J, Berman J, Garb JL, Rhee S, Friedmann P (1995) Synergistic effect of basic fibroblast growth factor and methylprednisolone on neurological function aTher experimental spinal cord injury. J Neurosurg 83:105-110.

Bartholdi D, Schwab ME (1997) Expression of pro-inflammatory cytokine and chemokine mRNA upon experimental spinal cord injury in mouse: an in situ hybridization study. Eur J Neurosci 9:1422-1438.

Basso DM, Beattie MS, Bresnahan JC (1995) A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 12:1-21.

Blight AR (1992) Macrophages and inflammatory damage in spinal cord injury. J Neurotrauma 9:83-91.

Charriaut-Marlangue C, Margaill I, Represa A, Popovici T, Plotkine M, Ben-Ari Y (1996) Apoptosis and necrosis after reversible focal ischemia: an in situ DNA fragmentation analysis. J Cereb Blood Flow Metab 16:186-194.

Collins WF (1983) A review and update of experimental and clinical studies of spinal cord injury. Paraplegia 21:204-219.

Crowe MJ, Bresnahan JC, Shuman SL, Masters JN, Beattie MS (1997) Apoptosis and delayed degeneration aTher spinal cord injury in rats and monkeys. Nat Med 3:73-76.

Díaz-Ruiz A, Ibarra A, Pérez-Severiano F, Guízar-Sahagún G, Grijalva I, Ríos C (2002) Constitutive and inducible nitric oxide synthase activities aTher spinal cord contusion in rats. Neurosci Lett 319:129-132.

Darzynkiewicz Z, Galkowski D, Zhao H (2008) Analysis of apoptosis by cytometry using TUNEL assay. Methods 44:250-254.

Genovese T, Mazzon E, Crisafulli C, Di Paola R, Muià C, Bramanti P, Cuzzocrea S (2006) Immunomodulatory effects of etanercept in an experimental model of spinal cord injury. J Pharmacol ExpTher 316:1006-1016.

Hall ED (1992) The neuroprotective pharmacology of methylprednisolone. J Neurosurg 76:13-22.

Hausmann ON (2003) Post-traumatic inflammation following spinal cord injury. Spinal Cord 41:369-378.

Hsu CY, Dimitrijevic MR (1990) Methylprednisolone in spinal cord injury: the possible mechanism of action. J Neurotrauma 7:115-119.

Hyong A, Jadhav V, Lee S, Tong W, Rowe J, Zhang JH, Tang J (2008). Rosiglitazone, a PPAR gamma agonist, attenuates inflammation aTher surgical brain injury in rodents. Brain Res 1215:218-224.

Kato H, Kanellopoulos GK, Matsuo S, Wu YJ, Jacquin MF, Hsu CY, Kouchoukos NT, Choi DW (1997) Neuronal apoptosis and necrosis following spinal cord ischemia in the rat. Exp Neurol 148:464-474.

Liu XZ, Xu XM, Hu R, Du C, Zhang SX, McDonald JW, Dong HX, Wu YJ, Fan GS, Jacquin MF, Hsu CY, Choi DW (1997). Neuronal and glial apoptosis aTher traumatic spinal cord injury. J Neurosci 17:5395-5406.

Lu B, Wang L, Stehlik C, Medan D, Huang C, Hu S, Chen F, Shi X, Rojanasakul Y (2006) Phosphatidylinositol 3-kinase/Akt positively regulates Fas (CD95)-mediated apoptosis in epidermal Cl41 cells. J Immunol 176:6785-6793.

Madeira JM, Schindler SM, Klegeris A (2015) A new look at auranofin, dextromethorphan and rosiglitazone for reduction of glia-mediated inflammation in neurodegenerative diseases. Neural Regen Res 10:391-393.

McTigue DM, Tani M, Krivacic K, Chernosky A, Kelner GS, Maciejewski D, Maki R, Ransohoff RM, Stokes BT (1989) Selective chemokine mRNA accumulation in the rat spinal cord aTher contusion injury. J Neurosci Res 53:368-376.

Mullane K (1989) Neutrophil-platelet interactions and post-ischemic myocardial injury. Prog Clin Biol Res 301:39-51.

Nadeau S, Rivest S (2003) Glucocorticoids play a fundamental role in protecting the brain during innate immune responses. J Neurosci 23:5336-5544.

Nash HH, Borke RC, Anders JJ (2002) Ensheathing cells and methylprednisolone promote axonal regeneration and functional recovery in the lesioned adult rat spinal cord. J Neurosci 22:7111-7120.

Park SW, Yi JH, Miranpuri G, Satriotomo I, Bowen K, Resnick DK, Vemuganti R (2007) Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation aTher spinal cord injury in adult rats. J Pharmacol Exp Ther 320:1002-1012.

Pereira MP, Hurtado O, Cárdenas A, Boscá L, Castillo J, Dávalos A, Vivancos J, Serena J, Lorenzo P, Lizasoain I, Moro MA (2006) Rosiglitazone and 15-deoxy-delta12, 14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J Cereb Blood Flow Metab 26:218-229.

Profyris C, Cheema SS, Zang D, Azari MF, Boyle K, Petratos S (2004) Degenerative and regenerative mechanisms governing spinal cord injury. Neurobiol Dis 15:415-436.

Rintala DH, Loubser PG, Castro J, Hart KA, Fuhrer MJ (1998) Chronic pain in a community-based sample of men with spinal cord injury:prevalence, severity, and relationship with impairment, disability, handicap, and subjective well-being. Arch Phys Med Rehabil 79:604-614.

Rivlin AS, Tator CH (1978) Effect of duration of acute spinal cord compression in a new acute cord injury model in the rat. Surg Neurol 10:38-43.

Sayer FT, Kronvall E, Nilsson OG (2006) Methylprednisolone treatment in acute spinal cord injury: the myth challenged through a structured analysis of published literature. Spine J 6:335-343.

Short DJ, El Masry WS, Jones PW (2000) High dose methylprednisolone in the management of acute spinal cord injury-a systematic review from a clinical perspective. Spinal Cord 38:273-286.

Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE (2005) Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 130:685-696.

Takami T, Oudega M, Bethea JR, Wood PM, Kleitman N, Bunge MB (2002) Methylprednisolone and interleukin-10 reduce gray matter damage in the contused Fischer rat thoracic spinal cord but do not improve functional outcome. J Neurotrauma 19:653-666.

Tolman KG, Chandramouli J (2003) Hepatotoxicity of the thiazolidinediones. Clin Liver Dis 7:369-379.

Wang CX, Olschowka JA, Wrathall JR (1997) Increase of interleukin-1beta mRNA and protein in the spinal cord following experimental traumatic injury in the rat. Brain Res 759:190-196.

Wu CH, Ding XY, Wang HY, Ye XB, Huang SY, Huang AM, Li HZ, Wu SY, Yu J, Yan XH (2006) Neural apoptosis and apoptosis-related genes in intracerebral hemorrhage patients. Zhonghua Yi Xue Za Zhi 86:3073-3076.

Yan P, Xu J, Li Q, Chen S, Kim GM, Hsu CY, Xu XM (1999) Glucocorticoid receptor expression in the spinal cord aTher traumatic injury in adult rats. J Neurosci 19:9355-9363.

Copyedited by Cooper C, Hindle A, Wang J, Qiu Y, Li CH, Song LP, Zhao M

10.4103/1673-5374.193250

*Correspondence to: